Emerging Drugs Network Of Australia: A Coordinated Toxicosurveillance System Of Illicit Drug Use In Australia To Enable Rapid Detection And Harm Reduction Responses Via An Early Warning System
Funder
National Health and Medical Research Council
Funding Amount
$3,722,731.00
Summary
The Emerging Drugs Network of Australia brings together emergency physicians, toxicologists and forensic laboratories across the country to build a national surveillance and early warning system of illicit and emerging drugs. Our innovative approach will use laboratory confirmed data to identify the specific drugs resulting in emergency department presentations, and use this information to inform rapid, evidence-based public health responses to reduce further drug-related harm in the community.
Determining The Impacts Of COVID-19 Restrictions On People Who Use Drugs
Funder
National Health and Medical Research Council
Funding Amount
$429,228.00
Summary
COVID-19 has resulted in unparalleled government interventions to close borders and restrict social interactions which have major implications for illicit drug supply, procurement and use practices, as well as responses. People who use drugs will be profoundly impacted by COVID-19 and so our study will leverage existing data collections to compare drug use practices and consequences before, during and after the COVID-19 interventions to determine COVID-19 impacts on people who use drugs.
Understanding Sex Differences In Alcohol Use Disorder: The Role Of Stress And Neuropeptides
Funder
National Health and Medical Research Council
Funding Amount
$692,106.00
Summary
Alcohol use disorders (AUD) are an emerging issue in women, yet there is little understanding of the how the male and female brains differ in response to excessive alcohol consumption. In pilot studies, we have found that deletion of a specific brain chemical causes differences in the way male and female mice consume alcohol in excess. We will further characterise this system and test new approaches to reduce the desire to consume alcohol.
Developing Novel Agents To Prevent Tumour Recurrence In Glioblastoma
Funder
National Health and Medical Research Council
Funding Amount
$1,089,561.00
Summary
Glioblastoma is a form of brain cancer that is currently incurable. We have discovered that switching-off an enzyme called KDM4 (using 'KDM4 inhibitors') improves chemotherapy outcomes with new drugs also discovered in our laboratory. This project will examine a novel drug combination treatment for glioblastoma patients and generate evidence for initiation of clinical trials. This could initiate a novel therapy that could significantly extend patients' lives.
Unravelling The Behavioural And Brain Mechanisms Of Compulsive Disorders, And New Ways To Treat Them
Funder
National Health and Medical Research Council
Funding Amount
$635,076.00
Summary
Disorders of compulsion, such as obsessive-compulsive disorder and substance use disorder, are chronic, debilitating, and present a significant cost to the individual and to society. Together, these disorders affect more than 10% of the population. Moreover, 40-60% of these individuals are resistant to current treatment. The current project is aimed at improving the preclinical research underlying our understanding the behavioural and brain mechanisms of such disorders and how to treat them.
Relaxin Receptor Structural Determination To Aid Therapeutic Development
Funder
National Health and Medical Research Council
Funding Amount
$1,249,114.00
Summary
The receptor for the peptide hormone relaxin, RXFP1, is being targeted by numerous drug companies for the treatment of cardiovascular disease. However, the lack of molecular detail of how relaxin binds and activates RXFP1 is hindering new drug development. We will determine the structure of the complex of relaxin bound to RXFP1 and the mechanism by which this activates cells. The knowledge gained will aid in the design of new drugs targeting RXFP1 for the treatment of cardiovascular disease.
Development Of Novel Anti-malaria Drugs That Block Parasite Invasion
Funder
National Health and Medical Research Council
Funding Amount
$1,035,623.00
Summary
Malaria is a devastating parasitic disease that kills over 400,000 people a year. Antimalarial drugs play a crucial role in helping eradicate malaria but of great concern is that parasites are becoming resistant to current drugs. We are developing drugs that prevent parasites from invading and proliferating in human blood which causes malaria. We are also discovering how the drugs work with the aim of greatly improving their performance towards clinical uptake.
Molecular Characterisation Of The DBHS Proteins In Telomerase Assembly
Funder
National Health and Medical Research Council
Funding Amount
$686,246.00
Summary
Telomerase is an enzyme that is active in over 90% of cancers. Telomerase activity allows cancer cells to divide an indefinite number of times. We have identified a novel role for the DBHS protein family in regulating telomerase activity. We aim to investigate the mechanisms by which these proteins function to assemble and transport telomerase to its site of action in the cell. We then aim to develop chemical inhibitors of these proteins, and test their utility in preventing cancer cell growth.
New Therapeutic Approaches For Genetic Skeletal Disorders
Funder
National Health and Medical Research Council
Funding Amount
$961,150.00
Summary
Genetic skeletal disorders are a significant disease burden with limited therapeutic options. We will use mouse models of cartilage and bone disorders and human induced pluripotent stem cell derived bone and cartilage 'disease in a dish' models to test repurposed FDA-approved drugs and new drug candidates as novel therapeutic strategies.
Validating CaMKK2 As A Rational Treatment Target For Bipolar Disorder
Funder
National Health and Medical Research Council
Funding Amount
$688,175.00
Summary
Bipolar disorder is a disabling, chronic mental illness that profoundly impairs the ability of affected individuals to function in daily life. Existing treatments for bipolar disorder are inadequate and lack the necessary efficacy and tolerability required for long-term therapy. This project will validate the enzyme, CaMKK2, as a rational treatment target for bipolar disorder, which will guide the development of more effective and safer drugs to improve patient outcomes.